Neodeca Injection

Adult dosage

<Central Venous Administration> Usually 400 to 800 mL per day (equivalent to 40 to 80 g of total amino acids) is continuously administered by slow intravenous drip according to high-calorie fluid therapy. Adjust dosage appropriately based on age, symptoms, and weight. <Peripheral Venous Administration> 200 to 400 mL (equivalent to 20 to 40 g of total amino acids) is slowly administered by intravenous drip. The infusion rate is based on total amino acids over 60 minutes.

Children's dosage

<Peripheral Venous Administration> Administer at a lower infusion rate.

This drug must be used under the direction of a physician. Patients with allergies to the components of this drug, severe hepatic disease, severe renal impairment, or certain metabolic disorders should not use it. Patients with cardiac or pulmonary problems or fluid overload should not be given this drug. Patients with dehydration or electrolyte imbalance must receive appropriate treatment before administration and use this drug cautiously. Patients with impaired liver or kidney function require dosage adjustment and regular monitoring of liver function and ammonia levels. Patients with asthma or those sensitive to sulfites should be cautious as allergic reactions or asthma attacks may occur. When using this drug, side effects such as rash, nausea, vomiting, chest pain, and elevated liver enzymes may occur, so consult a physician immediately if abnormal symptoms appear. In patients with severe renal impairment or hypernitrogenemia, the decision to administer the drug should be made carefully depending on the method of dialysis and condition. Regular blood tests and monitoring of fluid status are important, and it is essential to administer this drug with an appropriate energy source for protein synthesis. When used with glucose, blood sugar levels should be monitored periodically, and peripheral venous injections may cause venous irritation. This drug may promote folic acid deficiency, so folic acid should be administered daily alongside it. Women who are pregnant or breastfeeding have not established the safety of this drug, so it should only be used when the therapeutic benefits outweigh the risks. Safety in children has not been adequately established, so caution is needed. Elderly patients may have reduced physical function, so care should be taken to slow the infusion rate and reduce the dose. In cases of overdose, symptoms such as increased blood volume, electrolyte imbalances, and acidosis may occur, so administration should be stopped immediately if symptoms appear. To reduce the risk of infection, maintain strict aseptic conditions before administration, use the drug immediately after opening, and do not use any remaining drug. During administration, monitor electrolyte balance, administer slowly intravenously, and if vascular pain occurs, change the injection site or stop administration. Store in a sealed container to prevent air ingress, and store at room temperature between 1 to 30 degrees Celsius for safe preservation of the drug's efficacy.

Serious side effects

Severe allergic reaction (hives, severe swelling, chest tightness, difficulty breathing, cold sweats, pallor), asthma attack, liver impairment (jaundice), severe swelling or urination issues (decreased urine output, generalized edema, hypertension)

Mild side effects

• Rash
• nausea
• vomiting
• palpitations
• increased AST (GOT)
• ALT (GPT)
• total bilirubin
• elevated BUN
• acidosis
• chills

This drug should be stored in a sealed container to prevent air from entering, and it is safe to store at room temperature between 1 and 30 degrees Celsius. This storage method will help maintain the drug's efficacy.

Appearance

A transparent solution that is colorless or pale yellow, contained in a colorless transparent glass bottle for injection.

Package unit

200 milliliters/bottle, 250 milliliters/bottle